ArticleFEMS yeast research2010
Protection of the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection.
Article in FEMS yeast research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Article
- Salivary proteins modulate Candida albicans virulence and may prevent oropharingeal candidiasis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
- Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022Review
- Histatin 5 variant reduces Candida albicans biofilm viability and inhibits biofilm formation.Fungal genetics and biology : FG & B · 2021Article
- HPLC-MS identification and expression ofAIMS microbiology · 2021Article
- Chemokine CCL28 Is a Potent Therapeutic Agent for Oropharyngeal Candidiasis.Antimicrobial agents and chemotherapy · 2020Article
- Effects of histatin 5 modifications on antifungal activity and kinetics of proteolysis.Protein science : a publication of the Protein Society · 2020Article
- Digital Design of a Universal Rat Intraoral Device for Therapeutic Evaluation of a Topical Formulation againstInfection and immunity · 2019Article
- Antifungal Activity of Oleylphosphocholine onAntimicrobial agents and chemotherapy · 2018Article
- Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis.Antimicrobial agents and chemotherapy · 2016Article
- Article
- Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis.Antimicrobial agents and chemotherapy · 2014Article
- Impaired Histatin-5 Levels and Salivary Antimicrobial Activity againstJournal of AIDS & clinical research · 2013Article
- Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.Cytokine · 2012Review
- The novel Candida albicans transporter Dur31 Is a multi-stage pathogenicity factor.PLoS pathogens · 2012Article
- Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.Probiotics and antimicrobial proteins · 2011Article
- HIV infection and specific mucosal immunity: workshop 4B.Advances in dental research · 2011Article
- In vitro and ex vivo models of the oral mucosa as platforms for the validation of novel drug delivery systems.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The oral cavity is a primary target for opportunistic infections, particularly oral candidiasis caused by Candida albicans. A commensal fungus commonly colonizing mucosal surfaces, under conditions of immune dysfunction, C. albicans can become a pathogen causing recurrent infections. Yet, the role of host oral innate immunity in the development of candidiasis is not fully elucidated. Specifically, the host salivary antimicrobial peptide histatin-5 (Hst-5) has been proposed to play a protective role in the oral cavity against C. albicans. However, investigations demonstrating its efficacy on oral tissue have been lacking. To this end, in this study, an ex vivo murine model of oral infection was developed. Viable C. albicans counts and histopathological analyses demonstrated a significant protective effect for Hst-5 on mouse oral tissue against C. albicans. More importantly, host saliva exerted a comparable anticandidal effect. However, this effect was neutralized upon treatment of saliva with proteases and C. albicans, previously shown to degrade Hst-5, indicating that Hst-5 is likely the salivary component responsible for the observed protection. Combined, the findings from this study demonstrate for the first time the efficacy of salivary Hst-5 in protecting host oral tissue against C. albicans infection, thereby affirming the therapeutic potential of this natural host peptide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.